Associated Papers
Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer.
Borcoman E et al.
International Journal of Molecular Sciences, 2023
37511329 (PubMed )
Supplement: ijms-24-11570-s001.zip › ijms-2309018-supplementary.pdf
Molecular characteristics of young-onset colorectal cancer in Vietnamese patients.
Do MD et al.
Asia-pacific Journal of Clinical Oncology, 2022
35098669 (PubMed )
Supplement: supplement_1.xlsx › Sheet1
The genetic landscape of choroid plexus tumors in children and adults.
Thomas C et al.
Neuro-oncology, 2021
Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer.
Zeng B et al.
Frontiers in Oncology, 2021
33889545 (PubMed )
Supplement: Table_12.XLSX › Sheet1
TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer.
Hsu HC et al.
Cancers, 2019
31366114 (PubMed )
Supplement: cancers-11-01079-s001.zip › Supplementary_Table_2.xlsx › Supplementary_Table_2
FANCA D1359Y mutation in a patient with gastric polyposis and cancer susceptibility: A case report and review of literature.
Huang JP et al.
World Journal of Gastroenterology, 2018
PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients.
Hsu HC et al.
Cancers, 2018
30200630 (PubMed )
Supplement: cancers-10-00314-s001.zip › cancers-335170-sup › Supplementary_Table_S2.xlsx › Supplementary_Table_2
Next-generation sequencing in patients with advanced cancer: are we ready for widespread clinical use? A single institute's experience.
Grenader T et al.
Anti-cancer Drugs, 2016
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W et al.
Nature Genetics, 2013
24185512 (PubMed )
Supplement: NIHMS531250-supplement-2.xlsx › All_samples_N_36_
Select a paper to view details